A5025818195- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Lymphoma Diagnosis and Treatment
- Kruppel-like factors research
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Immunodeficiency and Autoimmune Disorders
National Specialized Hospital for Active Treatment of Hematologic Diseases
2016-2022
Objective: Chronic myelogenous leukemia (CML) is a disease, that in cases with high leukocyte numbers, treated hydration and cytoreductive therapy. Materials Methods:A 20-year-old female patient, during routine examination for pregnancy, presented elevated white blood cells (WBC) count (over 275x109/L) splenomegaly without any complaints. The diagnosis of Ph-positive CML was confirmed by cytology PCR [presence p210 type BCR::ABL1 [e13a2 (b2a2)] transcripts. Since she her 6th month abortion...
JAK2V617F mutation is a well-recognized feature in most Ph-negative myeloproliferative neoplasms (MPNs).An activated bone marrow (BM) angiogenesis has been established these disorders as well.Consequently, the rational question to ascertain possible relation among JAK2 mutation, morphological features and MPNs marrow.Aim: To assess microvessel density (MVD), cellularity fibrosis newly diagnosed patients with BCR-ABL-negative MPNs, define correlation between degree of mutant allele...
Aim: Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults.Unlike myeloid and acute lymphoblastic leukemia, treatment can be delayed after diagnosis.Exploration unique biology disease has led to identification more than 35 prognostic factors reported literature.In practice, however, number validated clinical biological significantly smaller.The purposes our study are: investigate distribution untreated CLL-patients according Binet staging as well analyse frequency...
e19068 Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of lymphomas, treated by rituximab-CHOP chemotherapy (R-CHOP). Prognostic stratification DLBCL patients (pts) done the enhanced International Index (NCCN-IPI) defining four risk groups [low (L), low-intermediate (LI), high-intermediate (HI) and high (H)]. Male gender considered as an adverse factor only in young pts. Recently serum albumin (SA), β2-microglobulin (B2M), peripheral blood lymphocyte/monocyte ratio...
Chronic lymphocytic leukemia (CLL) is one of the most common leukemias in adults. After 2000, FDA approved drugs for its treatment with mechanisms action different from those then-known cytostatics. This new therapeutic approach, employing targeted therapy, based on a better understanding biology and key pathogenetic driving development progression disease. Deletion long arm chromosome 13 frequently described cytogenetic aberrations among CLL patients, prognostic value which still debated,...